Eric Ende
Presidente presso MATINAS BIOPHARMA HOLDINGS, INC.
Patrimonio netto: 6 M $ in data 30/04/2024
Posizioni attive di Eric Ende
Società | Posizione | Inizio | Fine |
---|---|---|---|
MATINAS BIOPHARMA HOLDINGS, INC. | Independent Dir/Board Member | 03/04/2017 | - |
Presidente | 01/10/2022 | - | |
Direttore/Membro del Consiglio | 03/04/2017 | 01/10/2022 | |
AVADEL PHARMACEUTICALS PLC | Direttore/Membro del Consiglio | 01/12/2018 | - |
Independent Dir/Board Member | 01/12/2018 | - | |
Ende Consulting Group, Inc. | Presidente | 07/03/2011 | - |
Mesa Therapeutics, Inc. | Direttore/Membro del Consiglio | - | - |
Wellfit Holdings LLC
Wellfit Holdings LLC Information Technology ServicesTechnology Services Wellfit Holdings LLC provides computer programming services. The private company is based in Palm Beach Gardens, FL. The company was founded by Eric J. Ende. Eric J. Ende has been the CEO since incorporation. | Amministratore Delegato | - | - |
Direttore Finanziario/CFO | - | - | |
Fondatore | - | - | |
Ende Biomedical Consulting Group, Inc.
Ende Biomedical Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Ende Biomedical Consulting Group, Inc. provides biomedical consulting services. The private company is based in Palm Beach Gardens. | Presidente | 01/01/2009 | - |
Matinas BioPharma, Inc. | Direttore/Membro del Consiglio | 01/05/2017 | - |
Storia della carriera di Eric Ende
Precedenti posizioni note di Eric Ende
Società | Posizione | Inizio | Fine |
---|---|---|---|
NEUBASE THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 05/01/2022 | 12/05/2023 |
PROGENICS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 08/11/2019 | 19/06/2020 |
░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░ ░ ░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░░░░░░ | - | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formazione di Eric Ende
Emory University | Undergraduate Degree |
New York University | Masters Business Admin |
Icahn School of Medicine at Mount Sinai | Doctorate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 16 |
Irlanda | 2 |
Posizioni
Director/Board Member | 8 |
President | 2 |
Masters Business Admin | 2 |
Settori
Health Technology | 7 |
Consumer Services | 5 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
MATINAS BIOPHARMA HOLDINGS, INC. | Health Technology |
AVADEL PHARMACEUTICALS PLC | Health Technology |
Aziende private | 10 |
---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/
Merrill Lynch, Pierce, Fenner & Smith, Inc. /Old/ Investment Banks/BrokersFinance Merrill Lynch, Pierce, Fenner & Smith, Inc. (MLPFS) is the SEC-registered broker/dealer subsidiary of Merrill Lynch & Co., Inc., ultimately held by Charlotte-based Bank of America Corp. (NYSE: BAC). The firm was founded in 1958 and is headquartered in New York City. In 2010, Banc of America Securities LLC merged with MLPFS and the firm uses the trade name Bank of America Merrill Lynch. MLPFS's global strategy and economics team serves institutional and individual investors using a wide range of macroeconomic disciplines. Their analysis of global issues provides clients with investment ideas, market forecasts, macro overviews and specific sector recommendations across asset classes, regions and disciplines. Their equity research team conducts fundamental analysis on companies globally and provides institutional and retail clients with industry-specific and in-depth research and analysis on numerous industries. The firm's global fixed-income and equity-linked research focuses on fixed-income and equity derivatives, fixed-income strategy, convertibles, commodities, high-yield, mortgages, municipals and global foreign exchange. | Finance |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Matinas BioPharma, Inc. | |
Mesa Therapeutics, Inc. | |
Wellfit Holdings LLC
Wellfit Holdings LLC Information Technology ServicesTechnology Services Wellfit Holdings LLC provides computer programming services. The private company is based in Palm Beach Gardens, FL. The company was founded by Eric J. Ende. Eric J. Ende has been the CEO since incorporation. | Technology Services |
Ende Biomedical Consulting Group, Inc.
Ende Biomedical Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Ende Biomedical Consulting Group, Inc. provides biomedical consulting services. The private company is based in Palm Beach Gardens. | Commercial Services |
NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA. | Health Technology |
Ende Consulting Group, Inc. |
- Borsa valori
- Insiders
- Eric Ende
- Esperienza